Overview

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety of LX3305 in a dose escalation compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).
Phase:
Phase 1
Details
Lead Sponsor:
Lexicon Pharmaceuticals